RxDoctor Payments Data

Margaret Inge, DO

Family Medicine · Victoria, VANPI 1174934954

Payments from drug & device makers

$1,358in general payments, 2019–2025

Across 83 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • Lilly USA, LLC$152
  • Pfizer$149
  • Novo Nordisk$84
  • Abbott$69
  • GSK$64
  • plus $408 from 14 others

What the payments were for

  • Food & beverage$1,32097%
  • Other$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,358 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$5,840
Medicare patients
141
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide34$32,508
EliquisApixaban39$30,109
TradjentaLinagliptin32$26,595
JanuviaSitagliptin Phosphate29$24,144
ArexvyRsvpref3 Antigen/As01e/Pf73$23,429
JardianceEmpagliflozin14$18,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,286
OzempicSemaglutide15$14,485
LinzessLinaclotide22$12,955
XareltoRivaroxaban16$12,692
ShingrixVaricella-Zoster Ge/As01b/Pf36$7,922
FarxigaDapagliflozin Propanediol12$7,012
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,743
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,340
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Trelegy Ellipta, Shingrix$64$48,636135 claims
Lilly USA, LLCTrulicity$152$32,50834 claims
PfizerEliquis$149$30,10939 claims
MerckJanuvia$41$24,14429 claims
Novo NordiskOzempic$84$14,48515 claims
AbbVieLinzess$432$12,95522 claims
Johnson & JohnsonXarelto$16$12,69216 claims
AstraZenecaFarxiga$50$7,01212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Victoria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →